Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Open poster (ppt)


Bookmark and Share

OROS-Methylphenidate or Placebo for Adult Smokers with Attention Deficit Hyperactivity Disorder: Racial/Ethnic Differences.

Poster presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.

Lirio S. Covey, PhD (Columbia University Medical Center, LI Node), Mei-Chen Hu, PhD (Columbia University Mailman School of Public Health, NY Node), Theresa M. Winhusen, PhD (University of Cincinnati/CinARC, OV Node), Judith Weissman (Weill-Cornel Medical College), Ivan Berlin, MD, PhD (Hôpital Pitié-Salpêtrière, Paris, France), Edward V. Nunes, MD (New York State Psychiatric Institute, LI Node).

Race-related variations in drug response is recognized, but scant information exists on racial/ethnic differences in responses to smoking cessation treatments or methylphenidate. This study, a secondary analysis of data from protocol CTN-0029 ("A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD"), aimed to explore racial/ethnic differences in: the efficacy of OROS-Methylphenidate (OROS-MPH) on smoking abstinence as a function of ADHD treatment; the efficacy of OROS-MPH on ADHD symptoms, desire to smoke, and tobacco withdrawal symptoms when added to nicotine patch and behavioral counseling; and the effects of changes in those symptoms on the abstinence rate. The study found higher abstinence rates with OROS-MPH than placebo in non-white participants, but not in whites, however OROS-MPH reduced ADHD symptoms in both populations. OROS-MPH reduced desire to smoke in non-whites only, and decrease in desire to smoke from baseline predicted continuous abstinence during weeks 7-10. Results suggest that decrease in desire to smoke mediates the treatment effect on continuous abstinence and should be tested with larger and more homogenous samples of non-whites. (Poster, PowerPoint slides, English, 2010)

Keywords: African Americans | Attention Deficit Hyperactivity Disorder (ADHD) | Concerta | CTN platform/ancillary study | Hispanics and Latinos | Minority groups | Nicotine replacement therapy | Osmotic-Release Methylphenidate (OROS-MPH) | Pharmacological therapy | Smoking | NIDA Blending Conference, 2010

Document No: 463

Submitted by Edward Nunes, MD (LI Node), 5/19/2010.

Berlin, Ivan search
Covey, Lirio S. search mail
Hu, Mei-Chen search
Nunes, Edward V. search mail
Weissman, Judith search
Winhusen, Theresa M. search mail
NIDA-CTN-0029 search www
Ohio Valley (Lead) search www
Greater New York (formerly Long Island and New York) search www
New England Consortium (formerly Northern New England) search www
Western States (formerly Oregon/Hawaii) search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2010 --